HomeCompareNATI vs PFE

NATI vs PFE: Dividend Comparison 2026

NATI yields 1.87% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $8.8K in total portfolio value· pulled ahead in Year 10
10 years
NATI
NATI
● Live price
1.87%
Share price
$59.99
Annual div
$1.12
5Y div CAGR
33.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,941.70
Full NATI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NATI vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNATIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NATI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NATI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NATI
Annual income on $10K today (after 15% tax)
$158.69/yr
After 10yr DRIP, annual income (after tax)
$5,050.45/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $17,269.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NATI + PFE for your $10,000?

NATI: 50%PFE: 50%
100% PFE50/50100% NATI
Portfolio after 10yr
$45.2K
Annual income
$16,100.21/yr
Blended yield
35.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NATI
Analyst Ratings
3
Buy
11
Hold
Consensus: Hold
Price Target
$43.33
-27.8% upside vs current
Range: $35.00 — $52.00
Altman Z
5.5
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NATI buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNATIPFE
Forward yield1.87%6.13%
Annual dividend / share$1.12$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.5%13.2%
Portfolio after 10y$40.8K$49.6K
Annual income after 10y$5,941.70$26,258.71
Total dividends collected$18.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$43.33$27.50

Year-by-year: NATI vs PFE ($10,000, DRIP)

YearNATI PortfolioNATI Income/yrPFE PortfolioPFE Income/yrGap
1$10,949$249.24$9,153$693.39+$1.8KNATI
2$12,056$340.49$8,593$849.25+$3.5KNATI
3$13,368$467.76$8,336$1,066.78+$5.0KNATI
4$14,951$647.11$8,437$1,384.80+$6.5KNATI
5$16,900$902.97$9,013$1,875.40+$7.9KNATI
6$19,357$1,273.51$10,306$2,680.72+$9.1KNATI
7$22,532$1,819.86$12,820$4,101.38+$9.7KNATI
8$26,752$2,642.99$17,673$6,826.70+$9.1KNATI
9$32,540$3,915.20$27,543$12,591.86+$5.0KNATI
10← crossover$40,759$5,941.70$49,560$26,258.71$8.8KPFE

NATI vs PFE: Complete Analysis 2026

NATIStock

National Instruments Corporation provides a software-centric platform and systems to engineers and scientists worldwide. Its programming environments software includes NI LabVIEW, a graphical software platform to visualize hardware configuration, measurement data, and debugging of application; NI LabWindows/CVI, an ANSI C integrated development environment and engineering toolbox; and NI Measurement Studio, a suite of .NET tools for building engineering applications in Microsoft Visual Studio. The company's application software comprises NI TestStand that is used for automated test and measurement applications in manufacturing environment; NI VeriStand, a software environment for configuring real-time testing applications; Flexlogger for sensor configuration and data logging of mixed signals; and NI InsightCM Enterprise, a software for monitoring ancillary rotating equipment. Its operations management and analytic enterprise software include NI DIAdem, which is configuration-based technical data management, analysis, and report generation tools to mine and analyze engineering and measurement data; NI SystemLink, a systems management and data collection software that enables the mass coordination of connected devices, software deployments, and data communications throughout a distributed system; and NI Optimal Plus. The company also offers PXI hardware form factor; and NI semiconductor test systems, as well as software and hardware maintenance, and training and certification services. It serves semiconductor, transportation, aerospace, and defense industries; and government agencies. National Instruments Corporation has strategic agreements with Konrad Technologies, Inc. to develop test systems and solutions for autonomous driving software and hardware validation; and Foretellix Ltd. to enhance the safety of advanced driver-assistance systems and autonomous vehicles. The company was incorporated in 1976 and is headquartered in Austin, Texas.

Full NATI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NATI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NATI vs SCHDNATI vs JEPINATI vs ONATI vs KONATI vs MAINNATI vs JNJNATI vs MRKNATI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.